Northwest Biotherapeutics

Showcase Sponsor

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines.  The Company's DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and various potential  Phase II trials are anticipated, including in combination with checkpoint inhibitor drugs.  The Company's DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers,  and various potential Phase II trials are anticipated.


Sign Up for Event Updates